What Nectero Medical does

Nectero Medical, Inc. (DBA Nectero Therapeutics) is a clinical-stage biotech company headquartered in Tempe, Arizona, developing the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System, an investigational endovascular drug/device combination designed to stabilize growth and prevent rupture of small to mid-sized abdominal aortic aneurysms (AAA). The system uses a catheter-based approach to deliver a proprietary therapeutic mixture directly to the aneurysm site, where it is intended to strengthen aortic tissue, minimize further degradation of the aneurysm wall, and potentially delay or eliminate the need for major surgical intervention such as endovascular aneurysm repair (EVAR) or open surgery. The company targets an underserved population: AAA patients below the 5.5 cm (5.0 cm in women) surgical-intervention threshold who today are managed only by serial ultrasound or CT surveillance with no approved pharmacologic option to slow disease progression.

The Nectero EAST® System is investigational only and is not available for sale in the US; Nectero is currently advancing the asset through the Phase 2/3 stAAAble Clinical Study, with late-breaking clinical results presented at VIVA 2025. Nectero has raised approximately $115.5 million in disclosed venture financing, including a $96 million Series D in April 2024 led by Norwest with strategic participation from Boston Scientific, and is led by a multidisciplinary management team (Jack Springer, President & CEO) supported by an experienced board and physician leaders in vascular surgery. Its business model today is pre-commercial R&D funded by equity capital; future revenue mechanics, contingent on regulatory approval, are expected to flow through hospital-based catheterization labs and vascular surgery centers via a one-time license/sale model to clinicians and institutions that treat AAA patients.

Name

Nectero Medical

Legal name

Nectero Medical, Inc.

Website

https://necteromedical.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Nectero Medical (DBA Nectero Therapeutics) is a clinical-stage biotech developing the Nectero EAST System, an investigational endovascular treatment that stabilizes small to mid-sized abdominal aortic aneurysms to prevent rupture, serving AAA patients below the surgical threshold.

Ownership category

akta.pro rank

Product category

Vascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Measuring & Controlling Devices, Nec (3829)

akta.pro primary industry

Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG)

Keywords

• Vascular medical devices
• Endovascular aneurysm treatment
• Abdominal aortic aneurysm
• Clinical-stage therapeutics
• Minimally invasive vascular

Headquarters

HQ city

Tempe

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pre-commercialization: As a clinical-stage biotech company with an investigational product, Nectero Medical has no current commercial revenue. The company is developing its lead product through Phase 2/3 clinical trials with the goal of obtaining regulatory approval for commercialization.

Distribution channels1 record

Marketing channels1 record

Core offering

Nectero Medical is developing the Nectero EAST System, an investigational endovascular catheter-based treatment for patients with infrarenal abdominal aortic aneurysms (AAA). The system is currently being evaluated in the Phase 2/3 stAAAble Clinical Study. The company is pre-commercialization and the device has not yet received regulatory approval or market clearance.

Product overview

Nectero Medical (DBA Nectero Therapeutics) operates as a clinical-stage biotech company offering a single unified product: the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System. This investigational medical device uses an endovascular approach to deliver a proprietary mixture directly to the aneurysm site, with the goal of stabilizing aortic tissue, minimizing growth, and preventing rupture in patients with small to mid-sized abdominal aortic aneurysms.

Differentiator

Problem solved

Functional benefit

Brands

• Nectero EAST System: Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST) System - an investigational treatment using an endovascular approach to deliver a proprietary mixture to stabilize abdominal aortic aneurysms.

Products and services

• Nectero EAST System

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Artivion: Artivion (formerly CryoLife) acquired Endologix and is now a leading AAA stent graft company with products like AFX and Ovation. Directly comparable as an AAA-focused endovascular interventional player, though Artivion's products treat larger AAAs requiring repair versus Nectero's small/mid-sized stabilization approach.
• Lombard Medical: Lombard Medical is a smaller AAA-focused company with the Altura endograft system. Comparable as a focused AAA device company competing in the endovascular AAA space, similar in scale and strategic positioning to Nectero as a potential independent or tuck-in target.

Broad incumbents

• Medtronic: Medtronic is a global medtech incumbent with the Endurant II endograft system for AAA repair. Comparable as the dominant endovascular AAA player; its broad vascular portfolio, regulatory expertise, and deep hospital relationships make it a key incumbent that could extend into the small/mid-sized AAA segment.
• W. L. Gore & Associates: W. L. Gore manufactures the EXCLUDER and conformable EXCLUDER AAA stent grafts. Comparable as a major AAA endograft incumbent with established vascular surgery relationships; a potential competitor or strategic acquirer if Nectero validates the small/mid-sized AAA opportunity.
• Cook Medical: Cook Medical produces the Zenith Flex and Zenith Alpha AAA endograft systems. Comparable as a long-established AAA device incumbent with significant presence in vascular surgery centers globally, representing both a potential competitor and a strategic exit path.
• Terumo: Terumo is a global medical device company with a strong vascular interventional portfolio including guidewires, catheters, and access devices. Comparable as a broad incumbent in endovascular delivery systems; relevant given Nectero's endovascular delivery mechanism and as a potential strategic partner or acquirer.

Emerging players

• Penumbra: Penumbra is a high-growth vascular thrombectomy and interventional device company. Comparable as an endovascular interventional player focused on minimally invasive vascular procedures; relevant for endovascular delivery platform expertise and as a potential strategic acquirer for AAA expansion.
• Shockwave Medical: Shockwave Medical developed intravascular lithotripsy (IVL) for calcified lesions and was acquired by Johnson & Johnson. Comparable as an innovative endovascular interventional company; demonstrates the strategic value of disruptive endovascular technologies and the M&A appetite for such assets.
• Silk Road Medical: Silk Road Medical pioneered transcarotid artery revascularization (TCAR), a minimally invasive approach to carotid disease. Comparable as a minimally invasive vascular interventional company that has demonstrated how novel endovascular procedures can carve out defensible niches against incumbent surgical approaches.
• Surmodics: Surmodics develops drug-coated balloon and vascular drug-delivery surface technologies. Comparable as a company focused on localized drug delivery in the vasculature; relevant technology overlap with Nectero's proprietary drug/device combination approach to AAA stabilization.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nectero-medical-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nectero Medical